Oral Nirmatrelvir and Ritonavir for Covid-19 in Vaccinated, Non-Hospitalized Adults, Ages 18-50 Years.
Jemery Samuel FaustAshish KumarJui ShahSumanth KhadkeSourbha S DaniSarju GanatraPaul E SaxPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
NMV-r use in vaccinated adults aged 18-50, especially with serious comorbidities, was associated with reduced all-cause hospital visits, hospitalization, and mortality in the first 30 days of Covid-19 illness. However, NMR-r in patients without significant comorbidities or with only asthma/COPD had no association of benefit. Therefore, identifying high-risk patients should be a priority and avoid over-prescription should be avoided.
Keyphrases
- end stage renal disease
- coronavirus disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- chronic obstructive pulmonary disease
- healthcare
- peritoneal dialysis
- magnetic resonance
- lung function
- type diabetes
- emergency department
- high resolution
- coronary artery disease
- cardiovascular disease
- risk factors
- cardiovascular events